Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 31;12(1):117-123.
doi: 10.1093/toxres/tfad003. eCollection 2023 Feb.

Investigating the effect of myricetin against arsenic-induced cardiac toxicity in rats

Azadeh Aminzadeh  1   2 , Mohammad Hossein Darijani  1 , Hamideh Bashiri  3
Affiliations

Investigating the effect of myricetin against arsenic-induced cardiac toxicity in rats

Azadeh Aminzadeh et al. Toxicol Res (Camb). .

Abstract

Arsenic intoxication is a serious health hazard worldwide. Its toxicity is associated with several disorders and health problems in humans. Recent studies revealed that myricetin has various biological effects, including anti-oxidation. The aim of this study is to investigate the protective effect of myricetin against arsenic-induced cardiotoxicity in rats. Rats were randomized to one of the following groups: control, myricetin (2 mg/kg), arsenic (5 mg/kg), myricetin (1 mg/kg) + arsenic, and myricetin (2 mg/kg) + arsenic. Myricetin was given intraperitoneally 30 min before arsenic administration (5 mg/kg for 10 days). After treatments, the activity of lactate dehydrogenase (LDH) and the levels of aspartate aminotransferase (AST), creatine kinase myocardial band (CK-MB), lipid peroxidation (LPO), total antioxidant capacity (TAC), and total thiol molecules (TTM) were determined in serum samples and cardiac tissues. Also, histological changes in cardiac tissue were evaluated. Myricetin pretreatment inhibited arsenic-induced increase in LDH, AST, CK-MB, and LPO levels. Pretreatment with myricetin also enhanced the decreased TAC and TTM levels. In addition, myricetin improved histopathological alterations in arsenic-treated rats. In conclusion, the results of the present study demonstrated that treatment with myricetin prevented arsenic-induced cardiac toxicity at least in part by decreasing oxidative stress and restoring the antioxidant system.

Keywords: arsenic; cardiac toxicity; myricetin; oxidative stress; rats.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
Fig. 1
Fig. 1
Effect of myricetin on LDH, AST, and CK-MB in the serum of As-administered rats. Results are reported as the mean ± SD of six animals per group. &&&P < .001 compared with the control group. *P < .05, **P < .01, and ***P < .001 compared with the As group. As: arsenic; LDH: lactate dehydrogenase; AST: aspartate aminotransferase; CK-MB: creatine kinase myocardial band.
Fig. 2
Fig. 2
Effect of myricetin on the pathological morphology of cardiac tissues in As-administered rats (×200). (A) control group; (B) myricetin group; (C) As group; (D) As + myricetin 1 mg/kg group; (E) As + myricetin 2 mg/kg group.
Fig. 3
Fig. 3
Effect of myricetin on LPO levels of cardiac tissues and serum in As-administered rats. Results are reported as the mean ± SD of six animals per group. &&&P < .001 compared with the control group. *P < 0.05, **p < 0.01, and ***P < 0.001 compared with the As group. As: arsenic; LPO: lipid peroxidation.
Fig. 4
Fig. 4
Effect of myricetin on TAC of cardiac tissues and serum in As-administered rats. Results are reported as the mean ± SD of six animals per group. &&P < 0.01 and &&&P < 0.001 compared with the control group. *P < 0.05, **p < 0.01, and ***P < 0.001 compared with the As group. As: arsenic; TAC: total antioxidant capacity.
Fig. 5
Fig. 5
Effect of myricetin on TTM of cardiac tissues and serum in As-administered rats. Results are reported as the mean ± SD of six animals per group. &&P < 0.01 and &&&P < 0.001 compared with the control group. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the As group. As: arsenic; TTM: total thiol molecules.
See this image and copyright information in PMC

References

    1. Stummann T, Hareng L, Bremer S. Embryotoxicity hazard assessment of cadmium and arsenic compounds using embryonic stem cells. Toxicology. 2008:252:118–122. - PubMed
    1. Jomova K, Jenisova Z, Feszterova M, Baros S, Liska J, Hudecova D, Rhodes CJ, Valko M. Arsenic: toxicity, oxidative stress and human disease. J Appl Toxicol. 2011:31(2):95–107. - PubMed
    1. Ratnaike RN. Acute and chronic arsenic toxicity. Postgrad Med J. 2003:79:391–396. - PMC - PubMed
    1. Ravandi F, Koumenis I, Johri A, Tallman M, Roboz GJ, Strickland S, Garcia-Manero G, Borthakur G, Naqvi K, Meyer M, et al. Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica. 2020:105(6):1567–1574. - PMC - PubMed
    1. Zhu HH, Hu J, Lo-Coco F, Jin J. The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood. 2019:134:597–605. - PubMed